Effects Of Ivabradine On Left Ventricular Function In Patients With Ischemic Heart Disease

Yang Yang,Dao-Quan Peng

DOI: https://doi.org/10.1016/j.ijcard.2013.07.213

IF: 4.039

2013-01-01

International Journal of Cardiology

Abstract:With great interest, we read the recent article entitled with “Ivabradine significantly improves cardiac function in patients with ischemic heart disease: A meta-analysis of randomized controlled trials” [1]. The authors included 7 randomized controlled trials with a total of 1542 patients for meta-analysis and concluded that Ivabradine significantly improved cardiac function in patients with ischemic heart disease. In our opinion, this is an interesting manuscript analyzing the effects of Ivabradine on left ventricular function in patientswith ischemic heart disease. To enrich the study conducted by Peng et al., we have several comments as follows: Firstly, the authors performed an extensive search from6databases by using the following keywords/Medical Subject Headings: “Ivabradine plus myocardial infarction or angina or ischemic cardiomyopathy or heart failure or coronary artery disease or ischemic heart disease”. The search was restricted to “randomized controlled trial”. The literature search generated 482 publications of randomized controlled trials on Ivabradine for ischemicheartdisease.However, thedetailed searchalgorithmwasnot provided in the meta-analysis. A quick search using the online database “PubMed” with the search algorithm “(Ivabradine) AND randomized controlled trial” only generated 107 publications until July 4, 2013. And actually a considerable portion of the 107 results were not randomized controlled trials. According to the Cochrane Handbook [2], a thorough, objective and reproducible search strategy is critical to minimize the bias. Secondly, according to the authors, the criteria of an eligible study were: 1) randomized controlled trial; 2) patients with ischemic heart disease; 3) Ivabradine was used in one of the intervention group; and 4) outcome evaluation included LVEF as left ventricular function. The definition of ischemic heart disease in US National Library of Medicine was “A disorder of cardiac function caused by insufficient blood flow to the muscle tissue of the heart”. For the seven eligible studies in this meta-analysis, the primary criteria for including patientswere: “stable angina” [3]; “idiopathic dilated cardiomyopathy with chronic heart failure” [4]; “left ventricular dysfunction” [5]; “ischemic chronic heart failure” [6]; “stable coronary artery disease and left-ventricular systolic dysfunction” [7]; “early phases of reperfused anterior myocardial infarction with impaired left ventricular function” [8]; and “chronic heart failure” [9]. Due to the discrepancy between studies on the including criteria, it is highly possible that some patients included in the meta-analysis might not meet the diagnosis standard of ischemic heart disease. Thirdly, the characteristics of seven eligible studies were not summarized accurately in the main text, although the first table in the original article provided lots of information. In the study by Manz et al., [5] only a single intravenous dose of Ivabradine (0.25 mg/kg) was given to the patients and the left ventricular function was evaluated at 0 and 2 hours after injection. Ivabradine was administered